SB-T-121606

SB-T-121606 is a third-generation synthetic taxane, part of the Stony Brook taxanes (SB-T), developed to overcome multidrug resistance in cancer therapy. It demonstrates significantly higher efficacy than conventional paclitaxel (PTX) in resistant ovarian carcinoma and pancreatic ductal adenocarcinoma models. SB-T-121606 induces cell cycle arrest in the G2/M phase more effectively than PTX, with higher intracellular accumulation and antitumor activity in both in vitro and in vivo studies. In animal models, lower doses in combination with PTX can suppress tumor growth with manageable toxicity. Its mechanism mirrors that of other taxanes, targeting microtubules and disrupting cell division. The compound remains in preclinical development and has not yet reached clinical trial stages[1][2][3].

Other names

Stony Brook taxane 121606